Eli Lilly Raises 2026 Forecasts as GLP-1 Drug Demand Surges Globally
Recently, Eli Lilly revised its profit and revenue projections for the full year upward. This adjustment comes in response…
-
-
Ascletis Completes U.S. Phase II Enrollment for Oral GLP-1 Diabetes Drug ASC30
Ascletis Pharma has finished enrolling participants for a critical clinical trial. One hundred patients will test a new daily…
-
Oral Medication Prescriptions Surge as Development Pipeline Advances
According to recent research, the oral semaglutide formulation has a sizable lead in the developing pharmaceutical market. The top…
-
Oral Semaglutide Positions as First Oral GLP-1 Receptor Agonist for Pediatric Type 2 Diabetes
Novo Nordisk has revealed encouraging topline findings from PIONEER TEENS, a Phase III clinical trial assessing oral semaglutide in…
-
Amazon Enters GLP-1 Market With Integrated Weight Management Program Through One Medical
Amazon now offers a specialised weight management program through its subsidiary, One Medical. This initiative combines professional medical consultations…
-
Oral GLP-1 Medications Reshape the Expanding Pharmaceutical Market
The market for glucagon-like peptide-1 receptor agonists is currently undergoing a significant structural transformation. Oral formulations now demonstrate faster…
-
The GLP-1 Era: Redefining Weight Loss & Health
Pharmacological strategies for treating obesity and diabetes have been transformed by GLP-1 receptor agonists. Initially, these agents were aimed…
-
FDA Grants Approval to Orforglipron, Marking the First Freely Accessible Oral GLP-1 Treatment for Obesity
Regulatory bodies recently approved orforglipron for adults with obesity. This daily oral medication targets the glucagon-like peptide-1 receptor. It…
-
Eli Lilly’s Foundayo Receives FDA Approval as Oral GLP-1 Option, Backed by Amazon Distribution Partnership
The Food and Drug Administration recently approved a new medication called Foundayo. This daily pill helps adults who are…
-
Ro Launches Foundayo, Second Oral GLP-1 Option
Ro has recently expanded its obesity treatment portfolio by adding Foundayo, an oral GLP-1 receptor agonist. This new medication…
